Gyroscope Therapeutics

📍 London, United Kingdom🗓 Founded 2016👥 72 employees💰 Last funded Mar 2021
Biotechnology Research🌐 gyroscopetx.com
Website LinkedIn
About Gyroscope Therapeutics, a Novartis company: Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022. Gyroscope’s lead investigational gene therapy, GT005, is currently being evaluated in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness. GT005 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of people with GA. Guided by a mission to preserve sight and fight the devastating impact of blindness, Gyroscope has built a global organisation combining discovery, research, drug development, a manufacturing platform and surgical delivery capabilities.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Gyroscope Therapeutics?
Gyroscope Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers.
When did Gyroscope Therapeutics last raise funding?
The most recent investment in Gyroscope Therapeutics recorded on gritt.io was in March 2021.
When was Gyroscope Therapeutics founded?
Gyroscope Therapeutics was founded in 2016.
What industry is Gyroscope Therapeutics in?
Gyroscope Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Gyroscope Therapeutics based?
Gyroscope Therapeutics is headquartered in London, United Kingdom.